Rajan Dewar

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. pmc Bortezomib treatment causes remission in a Ph+ALL patient and reveals FoxO as a theranostic marker
    Rajan Dewar
    Department of Pathology, Harvard Medical School and Beth Israel Deaconess Medical Center, Boston MA, USA
    Cancer Biol Ther 11:552-8. 2011
  2. doi request reprint Best practices in diagnostic immunohistochemistry: myoepithelial markers in breast pathology
    Rajan Dewar
    Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215, USA
    Arch Pathol Lab Med 135:422-9. 2011

Detail Information

Publications2

  1. pmc Bortezomib treatment causes remission in a Ph+ALL patient and reveals FoxO as a theranostic marker
    Rajan Dewar
    Department of Pathology, Harvard Medical School and Beth Israel Deaconess Medical Center, Boston MA, USA
    Cancer Biol Ther 11:552-8. 2011
    ..Additionally, proteasomal inhibition by bortezomib may be a promising therapeutic option in Philadelphia-positive ALL, where FoxO3 is downregulated...
  2. doi request reprint Best practices in diagnostic immunohistochemistry: myoepithelial markers in breast pathology
    Rajan Dewar
    Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215, USA
    Arch Pathol Lab Med 135:422-9. 2011
    ....